Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Baumann

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|January 10, 2019
Kinetics and Predicted Structure of a Novel Xylose Reductase from <i>Chaetomium thermophilum</i>Julian Quehenberger, Tom Reichenbach, Niklas Baumann, et al.
Frontiers in Immunology|July 22, 2022
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?Chilam Chan, Marta Lustig, Niklas Baumann, et al.
Frontiers in Immunology|September 30, 2022
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?Chilam Chan, Marta Lustig, Niklas Baumann, et al.
Anesthesia and Analgesia|May 6, 2025
Spectral Differences of Anesthetic Agents: Addressing Fundamental Problems With New MethodsSrdjan Z Dragovic, Julian Ostertag, Niklas Baumann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2023
Bispecific Complement Engagers for Targeted Complement ActivationDennis V Pedersen, Heidi Gytz, Mikael B L Winkler, et al.
Scientific Reports|December 2, 2020
DNA aptamers against bacterial cells can be efficiently selected by a SELEX process using state-of-the art qPCR and ultra-deep sequencingClaudia Kolm, Isabella Cervenka, Ulrich J Aschl, et al.
Frontiers in Immunology|September 2, 2022
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumabNiklas Baumann, Christian Arndt, Judith Petersen, et al.
Blood Advances|September 15, 2021
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20Mitchell Evers, Thies Rösner, Anna Dünkel, et al.
Cancer Science|May 31, 2021
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactionsNiklas Baumann, Thies Rösner, J H Marco Jansen, et al.
Frontiers in Immunology|June 22, 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cellsMarta Lustig, Chilam Chan, J H Marco Jansen, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|January 10, 2019
Kinetics and Predicted Structure of a Novel Xylose Reductase from <i>Chaetomium thermophilum</i>Julian Quehenberger, Tom Reichenbach, Niklas Baumann, et al.
Frontiers in Immunology|July 22, 2022
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?Chilam Chan, Marta Lustig, Niklas Baumann, et al.
Frontiers in Immunology|September 30, 2022
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?Chilam Chan, Marta Lustig, Niklas Baumann, et al.
Anesthesia and Analgesia|May 6, 2025
Spectral Differences of Anesthetic Agents: Addressing Fundamental Problems With New MethodsSrdjan Z Dragovic, Julian Ostertag, Niklas Baumann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 23, 2023
Bispecific Complement Engagers for Targeted Complement ActivationDennis V Pedersen, Heidi Gytz, Mikael B L Winkler, et al.
Scientific Reports|December 2, 2020
DNA aptamers against bacterial cells can be efficiently selected by a SELEX process using state-of-the art qPCR and ultra-deep sequencingClaudia Kolm, Isabella Cervenka, Ulrich J Aschl, et al.
Frontiers in Immunology|September 2, 2022
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumabNiklas Baumann, Christian Arndt, Judith Petersen, et al.
Blood Advances|September 15, 2021
The selection of variable regions affects effector mechanisms of IgA antibodies against CD20Mitchell Evers, Thies Rösner, Anna Dünkel, et al.
Cancer Science|May 31, 2021
Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactionsNiklas Baumann, Thies Rösner, J H Marco Jansen, et al.
Frontiers in Immunology|June 22, 2023
Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cellsMarta Lustig, Chilam Chan, J H Marco Jansen, et al.
Pageof 2